Drug or treatment

Firmonertinib clinical trials

• 7Clinical trials
• 17Countries

Newest trials

All recruiting trials (7)

• Firmonertinib given before surgery for EGFR-mutated NSCLC

  This study tests whether taking firmonertinib before and around surgery helps patients with resectable EGFR-mutated NSCLC see more tumor shrinkage before the operation.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07622706

• Firmonertinib with definitive radiotherapy for unresectable Stage III NSCLC with EGFR uncommon mutations

  This trial tests whether adding Firmonertinib to definitive radiotherapy helps people with unresectable Stage III NSCLC that has uncommon EGFR mutations.

  Recruiting Phase 2 Hunan Cancer Hospital · Changsha, Hunan · NCT07314216

• Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations

  This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.

  Recruiting at 141 sites Phase 3 ArriVent BioPharma, Inc. · Fullerton, California and 140 other locations · NCT07185997

• High-dose firmonertinib plus chemotherapy injected into the spinal fluid for EGFR-mutant NSCLC with leptomeningeal spread

  This tests whether high-dose firmonertinib combined with chemotherapy injected into the spinal fluid helps people with EGFR-mutant non-small cell lung cancer that has spread to the leptomeninges.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07092202

• Firmonertinib versus placebo as additional treatment after surgery for stage IB–IIIB non‑small cell lung cancer with uncommon EGFR mutations

  This trial will test whether taking firmonertinib after complete lung cancer surgery helps prevent recurrence in people with stage IB–IIIB NSCLC that has uncommon EGFR mutations.

  Recruiting at 2 sites Phase 3 Allist Pharmaceuticals, Inc. · Beijing, Beijing Municipality and 1 other locations · NCT07010419

• Comparing firmonertinib to chemotherapy for advanced lung cancer with specific mutations

  This study is testing whether a new drug called firmonertinib can work better than standard chemotherapy for people with advanced lung cancer who have specific genetic mutations.

  Recruiting at 2 sites Phase 3 Allist Pharmaceuticals, Inc. · Beijing, Beijing Municipality and 1 other locations · NCT06956001

• Combination therapy for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs to see if they can help people with advanced lung cancer that has certain mutations feel better and live longer.

  Recruiting Phase 2 Abbisko Therapeutics Co, Ltd · Hefei, Anhui and 4 other locations · NCT06668103

Quick answers

How many clinical trials of Firmonertinib are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in China (7 trials), Australia (1 trial), Canada (1 trial), France (1 trial), Greece (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 3, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →